UNSPSC 51311808: Clemizole sulfate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H20ClN3.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5AA1G805H0, chemically known as 1h-benzimidazole, 1-((4-chlorophenyl)methyl)-2-(1-pyrrolidinylmethyl)- but more generally known as clemizole sulfate, which bears US NIH Compound Identifier 2782. Most nations, for tariff and trade purposes, schedule clemizole sulfate under HS 29339990 and SITC 51577. As of Q4 2014, CLEMIZOLE SULFATE remains US FDA's Preferred Term for this commodity.

Clemizole sulfate bears US NLM identifiers UMLS ID C3273572 and NCI Concept Code C97694. SMILES: C1CCC2C(C1)NC(N2CC3CCC(CC3)CL)CN4CCCC4.OS(=O)(=O)O.

UNSPSC 51311808 Clemizole sulfate is a Commodity code covering pharmaceutical active ingredients and finished drugs procured by state and local health agencies. The recent solicitations tagged under this code reveal a mismatch: clemizole sulfate is a veterinary antihistamine with minimal human pharmaceutical use, yet the opportunities posted show state and local governments buying naloxone, generic multi-source pharmaceuticals, and over-the-counter products through pharmacy benefit programs and cooperative purchasing vehicles. The code's nominal scope does not align with the actual procurement activity currently surfacing under it, suggesting either a data-tagging error or that clemizole sulfate represents a narrow subcategory within a broader pharmaceutical-procurement code that state and local systems are using for general drug sourcing.

The three most recent opportunities involve health agencies and cooperative purchasing consortia across Florida, Texas, and Minnesota. Seminole County, Florida posted an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with FEMA potential funding and standard insurance and compliance requirements. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) to explore direct-to-manufacturer prescription programs as an alternative to pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, requiring vendors to work through three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards. The code shows sparse recent activity that does not correspond to clemizole sulfate procurement.